Physician profile
Norbert Urbanski
NPI 1437364973
$5,695.65
in general payments reported to CMS, 2019-2025
28 companies · $33.57 in 2025
The $33.57 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,082 · 2020: $1,056 · 2021: $2,697 · 2022: $797 · 2023: $15.98 · 2024: $14.24 · 2025: $33.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $63.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $63.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $837.75 | 2021 | |
| Amgen INC. | $813.78 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $735.76 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $510.29 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $447.85 | 2019-2025 | Lifevest |
| Esperion Therapeutics, INC. | $362.93 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $326.20 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $323.23 | 2019-2022 | |
| Amarin Pharma, INC. | $203.06 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $177.14 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $149.88 | 2019-2021 | |
| Medtronic Vascular, INC. | $123.43 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $119.09 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $105.24 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $87.26 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $84.28 | 2021-2022 | |
| Boston Scientific Corporation | $41.88 | 2022 | |
| Gilead Sciences, INC. | $38.41 | 2019 | |
| Irhythm Technologies, INC. | $25.18 | 2019 | |
| Medicure Pharma INC. | $24.81 | 2021 | |
| Edwards Lifesciences Corporation | $24.74 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $24.58 | 2019 | |
| Abbott Laboratories | $23.82 | 2021 | |
| Astellas Pharma US INC | $21.51 | 2019 | |
| Vifor Pharma, INC. | $18.94 | 2021 | |
| Cmp Pharma, INC. | $18.68 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $13.85 | 2019 | |
| Philips North America LLC | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norbert Urbanski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.